Vedolizumab treatment persistence and safety in a 2-year data analysis of an extended access programme.

Silvio DaneseKavitha SubramaniamJan Van ZylShashi AdsulDirk LindnerJeannine RothSeverine Vermeire

Published in: Alimentary pharmacology & therapeutics (2020)

We observed high patient persistence on vedolizumab Q8W in the first 2 years after the reduction of dosing frequency in the XAP along with low rates of Q4W dose re-escalation and relapse. The safety profile was consistent with previous reports. ClinicalTrials.gov: NCT02743806.

Keyphrases

ulcerative colitis
patients with inflammatory bowel disease
case report
electronic health record
study protocol
big data
open label
randomized controlled trial
emergency department
machine learning
adverse drug
combination therapy
drug induced